Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.86 USD | +4.03% | +4.90% | -16.71% |
Business Summary
Number of employees: 704
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutic Compounds
100.0
%
| 75 | 100.0 % | 397 | 100.0 % | +425.83% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 75 | 100.0 % | 397 | 100.0 % | +425.83% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
Caroline Baumal
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-01-02 |
Adam Townsend
COO | Chief Operating Officer | 47 | 18-11-19 |
Lukas Scheibler
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-03-31 |
Meredith Kaya
IRC | Investor Relations Contact | - | - |
Jeffrey Eisele
PRN | Corporate Officer/Principal | - | 19-12-31 |
Vahe Ghahraman
LAW | General Counsel | - | 19-03-31 |
Thomas Lackner
PRN | Corporate Officer/Principal | - | 19-01-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
Director/Board Member | 65 | 13-06-30 | |
Andrew Dunlop
BRD | Director/Board Member | 52 | 10-02-28 |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Founder | 54 | 09-09-24 | |
Lok Chung Chan
CHM | Chairman | 73 | 13-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 120,581,749 | 104,637,200 ( 86.78 %) | 0 | 86.78 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.71% | 6.05B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- APLS Stock
- Company Apellis Pharmaceuticals, Inc.